Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
by Zacks Equity Research
The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
Abbott Up 7.7% Post Q2 Earnings: Should You Buy ABT Stock?
by Urmimala Biswas
Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.
Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall
by Zacks Equity Research
Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.
Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up
by Zacks Equity Research
Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.
National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook
by Zacks Equity Research
National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
by Zacks Equity Research
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
by Zacks Equity Research
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
by Zacks Equity Research
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.
Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.
CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook
by Zacks Equity Research
CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised
by Zacks Equity Research
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.
IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.
Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
by Zacks Equity Research
Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
Abbott (ABT) Just Overtook the 200-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.
Teleflex (TFX) Tops Q2 Earnings Estimates, Raises 2024 Outlook
by Zacks Equity Research
Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
by Mark Vickery
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.